143 related articles for article (PubMed ID: 38745197)
1. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy.
Vervuurt M; Kuiperij HB; de Kort AM; Kersten I; Klijn CJM; Schreuder FHBM; Verbeek MM
Alzheimers Res Ther; 2024 May; 16(1):108. PubMed ID: 38745197
[TBL] [Abstract][Full Text] [Related]
2. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
3. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
De Kort AM; Kuiperij HB; Marques TM; Jäkel L; van den Berg E; Kersten I; van Berckel-Smit HEP; Duering M; Stoops E; Abdo WF; Rasing I; Voigt S; Koemans EA; Kaushik K; Warren AD; Greenberg SM; Brinkmalm G; Terwindt GM; Wermer MJH; Schreuder FHBM; Klijn CJM; Verbeek MM
Ann Neurol; 2023 Jun; 93(6):1173-1186. PubMed ID: 36707720
[TBL] [Abstract][Full Text] [Related]
4. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
De Kort AM; Kaushik K; Kuiperij HB; Jäkel L; Li H; Tuladhar AM; Terwindt GM; Wermer MJH; Claassen JAHR; Klijn CJM; Verbeek MM; Kessels RPC; Schreuder FHBM
Alzheimers Res Ther; 2024 May; 16(1):99. PubMed ID: 38704569
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients.
Vervuurt M; Schrader JM; de Kort AM; Kersten I; Wessels HJCT; Klijn CJM; Schreuder FHBM; Kuiperij HB; Gloerich J; Van Nostrand WE; Verbeek MM
Acta Neuropathol Commun; 2024 Jan; 12(1):6. PubMed ID: 38191511
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
7. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
8. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease.
Andersson E; Janelidze S; Lampinen B; Nilsson M; Leuzy A; Stomrud E; Blennow K; Zetterberg H; Hansson O
Neurobiol Aging; 2020 Nov; 95():143-153. PubMed ID: 32810755
[TBL] [Abstract][Full Text] [Related]
9. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis.
Le ND; Muri L; Grandgirard D; Kuhle J; Leppert D; Leib SL
J Neuroinflammation; 2020 Oct; 17(1):293. PubMed ID: 33028339
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
12. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
13. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy.
Vervuurt M; de Kort AM; Jäkel L; Kersten I; Abdo WF; Schreuder FHBM; Rasing I; Terwindt GM; Wermer MJH; Greenberg SM; Klijn CJM; Kuiperij HB; Verbeek MM
Alzheimers Res Ther; 2023 Jan; 15(1):26. PubMed ID: 36717932
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy.
Vervuurt M; Zhu X; Schrader J; de Kort AM; Marques TM; Kersten I; Peters van Ton AM; Abdo WF; Schreuder FHBM; Rasing I; Terwindt GM; Wermer MJH; Greenberg SM; Klijn CJM; Kuiperij HB; Van Nostrand WE; Verbeek MM
Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12804. PubMed ID: 35266166
[TBL] [Abstract][Full Text] [Related]
15. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
[TBL] [Abstract][Full Text] [Related]
16. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
17. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM
Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume.
Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Grau-Rivera O; Operto G; Gispert JD; Vilor-Tejedor N; Sala-Vila A; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Molinuevo JL;
Neurobiol Aging; 2021 Aug; 104():24-31. PubMed ID: 33962331
[TBL] [Abstract][Full Text] [Related]
19. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment: A systematic review and meta-analysis.
Zhang J; Cheng H; Liu W; Li H; Song Y; Jia L
Medicine (Baltimore); 2022 Mar; 101(9):e28932. PubMed ID: 35244049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
